ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1892

Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery

Michael George1, Joshua Baker 2, Kevin Winthrop 3, Lang Chen 4, Qufei Wu 2, Fenglong Xie 5 and Jeffrey Curtis 4, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Oregon Health and Science University, Portland, OR, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: glucocorticoids and Biologics, Perioperative management, Rheumatoid arthritis (RA), surgery

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: 4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to evaluate the impact of glucocorticoids and biologics on outcomes after other major surgeries.

Methods: Using Medicare claims data 2006-2015 we identified adults with ≥2 diagnoses of RA who received methotrexate, a TNF inhibitor, abatacept, rituximab, tocilizumab, or tofacitinib within 6 months before major surgery and had 1 year of continuous prior Medicare enrollment (baseline). Hip fracture repair, abdominal surgeries (cholecystectomy, hysterectomy, hernia surgery, appendectomy, colectomy for diverticular disease), and cardiac surgeries (coronary artery bypass graft, mitral or aortic valve surgery) were identified based on primary ICD-9 procedure codes from inpatient hospitalization using established definitions. Patients with malignancy or HIV and patients with another major surgery within 6 months were excluded. Inverse probability weighted logistic regression models assessed association between average glucocorticoid dose in the 90 days before surgery (none, ≤5mg, 5-10mg, >10mg) and risk of 90-day mortality and 30-day readmission (among patients discharged to home, skilled nursing facility, or inpatient rehabilitation). Propensity score models included surgery type, elective vs. non-elective surgery, demographics, and measures of healthcare utilization, comorbidities, and previous infection during the baseline period. Separate models with recalculated propensity scores compared risk of these outcomes in patients receiving a biologic or targeted synthetic DMARD (tsDMARD) vs. patients exposed to methotrexate without biologics/tsDMARDs, requiring patients to have an infusion or prescription within 8 weeks before surgery.

Results: We identified 13544 surgeries meeting all inclusion and exclusion criteria, including 4328 hip fracture surgeries, 6403 abdominal surgeries, and 2813 cardiac surgeries. Glucocorticoids were associated with a dose-dependent increase in the risk of 90-day mortality and 30-day readmission, although associations were partially attenuated in propensity weighted models (Table 2). Associations with mortality were strongest among patients undergoing cardiac surgery, while associations with 30-day readmission were similar across surgeries (Table 3). Among the 10677 (78.8%) of patients who received their biologic/tsDMARD or methotrexate within 8 weeks of surgery, we found no significant increase in the risk of 90-day mortality or 30-day readmission in patients receiving a TNF or patients receiving a non-TNF biologic/tsDMARD vs. patients receiving methotrexate, with similar results across surgery types (Tables 2-3).

Conclusion: Glucocorticoids are associated with greater risk of adverse outcomes after major surgery, especially at higher doses. Recent exposure to biologics/tsDMARDs, however, is not associated with increased mortality or readmission.


Disclosure: M. George, AbbVie, 5, Bristol Myers Squibb, 2, Bristol-Myers Squibb, 2; J. Baker, Bristol-Myers Squibb, 2, 5, Burns-White LLC, 5; K. Winthrop, AbbVie, 5, Abbvie, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Galapagos, 5, Galapagos NV, 5, Gilead, 5, Gilead Sciences, Inc., 5, GSK, 5, Lilly, 5, Pfizer, 2, 5, Roche, 5, UCB, 5, UCB Pharma, 5, UCB Pharma, Pfizer, Bristol-Myers Squibb, Eli Lilly, AbbVie, and Roche., 2, 5; L. Chen, None; Q. Wu, None; F. Xie, None; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5.

To cite this abstract in AMA style:

George M, Baker J, Winthrop K, Chen L, Wu Q, Xie F, Curtis J. Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/association-between-rheumatoid-arthritis-treatment-and-the-risk-of-death-or-readmission-after-major-surgery/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-rheumatoid-arthritis-treatment-and-the-risk-of-death-or-readmission-after-major-surgery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.